Welcome to our dedicated page for JHB news (Ticker: JHB), a resource for investors and traders seeking the latest updates and insights on JHB stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect JHB's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of JHB's position in the market.
The Nuveen Corporate Income Target Term Fund (NYSE: JHB) has completed its termination and liquidation as of November 1, 2021. Due to recent market conditions, the fund returned a liquidating NAV of $9.4061 per share, below its original NAV of $9.85. Over its five-year term, the fund distributed a total of $2.3789 per share, averaging a distribution rate of 4.65%. Shareholders may recognize gains or losses for U.S. tax purposes due to the liquidation. For further details, visit Nuveen's website.
